Vor Biopharma Inc. (NYSE:VOR) Given Average Recommendation of “Buy” by Analysts

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned an average recommendation of “Buy” from the five brokerages that are covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $13.50.

A number of analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Vor Biopharma in a research report on Thursday, March 21st. HC Wainwright reaffirmed a “buy” rating and set a $17.50 target price on shares of Vor Biopharma in a research report on Thursday, March 21st. Oppenheimer reissued an “outperform” rating and issued a $15.00 price target (down previously from $17.00) on shares of Vor Biopharma in a research report on Thursday, March 21st. JMP Securities restated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a report on Friday, March 22nd. Finally, Stifel Nicolaus dropped their price objective on shares of Vor Biopharma from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, March 21st.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds have recently bought and sold shares of VOR. Bank of Montreal Can bought a new position in shares of Vor Biopharma during the first quarter valued at about $283,000. Ergoteles LLC purchased a new position in shares of Vor Biopharma in the 1st quarter worth approximately $97,000. State Street Corp grew its holdings in shares of Vor Biopharma by 6.7% in the first quarter. State Street Corp now owns 283,076 shares of the company’s stock valued at $1,710,000 after acquiring an additional 17,891 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Vor Biopharma by 48.6% during the first quarter. Goldman Sachs Group Inc. now owns 25,607 shares of the company’s stock valued at $155,000 after acquiring an additional 8,370 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Vor Biopharma during the second quarter worth $86,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Trading Up 2.3 %

VOR opened at $2.21 on Friday. The company has a market cap of $150.66 million, a P/E ratio of -1.26 and a beta of -0.38. The company has a fifty day moving average price of $2.16 and a two-hundred day moving average price of $2.14. Vor Biopharma has a 1-year low of $1.62 and a 1-year high of $5.80.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.